RxDoctor Payments Data

Suyon Rhee, DPM

Podiatrist · Hattiesburg, MSNPI 1871601062

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Smith+Nephew at 37.3% of the total. That places this record below the midpoint for podiatrist clinicians in MS, where the typical reported total is $566.

$461in general payments, 2019–2025

Across 24 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$172
  • Averitas Pharma Inc.$86
  • Paratek Pharmaceuticals, Inc.$45
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$43
  • Medtronic$36
  • Abbott$25
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$461 in reported general payments places this provider in the 45th percentile of 28 podiatrist providers in Mississippi.

See all podiatrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$229,225
Medicare patients
1,022
Services billed
4,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine692$17,631
JubliaEfinaconazole11$8,200
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav75$896
Terbinafine Hcl88$612
Ammonium Lactate23$579
Doxycycline Hyclate61$391
Amoxicillin75$388
Ketoconazole12$384
Mupirocin43$316
Clindamycin Hcl18$192
Diclofenac Sodium17$185
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim49$149
Methylprednisolone25$147
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$43$8,20011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 28 podiatrist providers in Mississippi.

Other podiatrist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →